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Abstract 
Antimicrobial peptides are a promising resource for developing novel antibiotic and even 
anticancer drugs. Here, a 28-mer polypeptide, R2PLx, was identified from lyophilised skin 
secretions. The chemically-synthetic replicates exhibited moderate and broad-spectrum 
antimicrobial effect against various microorganisms including methicillin-resistant S. aureus 
(MRSA, MIC=256 µM). In additional, R2PLx was found to inhibit the proliferation of several 
tumour cells, especially showing more potent effect on prostate cancer cell, PC-3. The early 
cell apoptosis was observed in 6 h by Annexin V-FITC/PI staining, as well as the activation 
of Caspase-3 at 5 µM peptide concentration. R2PLx may therefore be promising for 
developing new therapeutic approach for cancer treatment. In addition, the artificial 
deficiency of conserved rana-box loop or net positive charge in C-terminal domain notably 
reduced the biological activities of the truncated and substituted isoforms, respectively, 
suggesting for maintaining their biological potency of Ranatuerin family requires both 
cysteine-bridged segment and cationincity within the loop domain in C-terminus.  
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INTRODUCTION 
As a crucial part of host innate defensive system, antimicrobial peptides (AMPs), secreted by 
amphibian granular glands, are ideal candidates to examine as potential novel antibiotic 
alternatives which could combat multi-drug resistant bacterial strains 
[1-3]
. Apart from their 
broad-spectrum antibacterial capabilities, reports have also indicated these peptides may also 
have potential in other fields due to their tumoricidal, antiviral and immunomodulatory 
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[4]
. Previous research has revealed these amphibian skin-derived AMPs are diverse 
in their primary sequences, though they are commonly hydrophobic, cationic and able to form 
an amphipathic helix in a membrane-mimetic solvent 
[4, 5]
. 
    Ranatuerins, a canonical family of anuran AMPs, was initially identified from genus 
Rana and generally they display broad-spectrum antibacterial activity against a range of 
ubiquitous pathogens, along with comparatively low haemolytic activity 
[6-8]
. Ranatuerin-2 is 
a predominant family member which consists of a N-terminal α-helix domain, and contains 
the conserved domains, including Gly
1
, Lys
22
, and the heptapeptide C-terminal
 “Rana box” [8-
11]
. Several similar isoforms have also been identified from North American Rana frogs, such 
as ranatuerin-2VEa and -2VEb, and ranatuerin-2Oa and -2Oe have been identified from the 
Chinese bamboo leaf odorous frog and Japanese brown frogs 
[9, 10]
.  
    Herein, we describe the discovery of a biosynthetic precursor, preproranaturin-2, 
encoding an antimicrobial peptide, R2PLx, from the skin secretions of the pickerel frog (Rana 
palustris) using a combination of “shotgun” cloning and mass spectrometry. The 
corresponding chemically synthesised replicate exerted antibacterial activities towards 
pathogenic microorganisms and anti-proliferative activity towards tumour cells by inducing 
apoptosis. In addition, we demonstrate that deleting the conserved rana-box loop drastically 
reduces the antibacterial and anti-proliferative activities of this peptide. 
MATERIALS AND METHODS  
Acquisition of dermal secretions from pickerel frog 
Twelve specimens of mature pickerel frog (scale between 4-5cm length) were exposed to 12h 
of light at 18-25 °C daily and multivitamin-loaded crickets were provided as the fodder three-
time/week. Following four-month breeding, dermal secretions were obtained via surface 
electrical stimulation introduced by Tyler and co-workers in 1992 under proper Home Office 
(UK) animal licences (project licence PPL 2694). In summary, the skin surface was 
moistened with de-ionized water, followed by two periods of transdermal electric stimulation 
(6 V, 50Hz, 4ms pulse width), each of 20s duration. Finally, the secretions collected by gently 
flushing the frog skin with de-ionized water were lyophilized and stored at -20°C until mRNA 
extraction.  
Cloning and sequencing of a cDNA encoding R2PLx peptide precursor 
The intact polyadenylated mRNA was refined from crude lysate among five-milligram of 
lyophilized secretions via Dynabeads® mRNA DIRECT™ Kit (Invitrogen). Following 
reverse transcription, the full-length sequence of the mRNA transcript encoding the R2PLx 
peptide precursor was captured using the SMART-RACE kit (Clontech UK). Specifically, a 
supplied NUP primer and a degenerate primer (S1; 5’-
GAWYYAYYHRAGCCYAAADATG-3’) were employed in molecular cloning. In addition, 
the degenerate primer was designed to a highly-conserved domain of the 5’-untranslated 
region of previously-characterized homologous peptide cDNAs from Rana. Thereafter, 
RACE-products were subjected to purification, molecular cloning, and sequenced using Cycle 
Pure Kit (Omega Bio-Tek, USA), pGEM-T vector system (Promega Corporation), and ABI 
3100 automated sequencer respectively. 
Elucidation of R2PLx in structural characterization  
After centrifugation (2500 ×g, 5 min) from 10 mg/ml secretion solution dissolved in 0.05/99.5 
(v/v) trifluoroacetic acid (TFA)/water, the clear supernatant was subjected to RP-HPLC 
column (Jupiter C5; 250 mm × 4.6 mm, Phenomenex, UK) on a Cecil CE4200 Adept gradient 
system (Cambridge, UK) (a gradient formed from 0.05/99.5 (v/v) TFA/water to 
0.05/19.95/80.0 (v/v/v) TFA/water/acetonitrile in 240 min at a flowrate of 1 ml/min). 
Subsequently, fractions were taken every minute and each was analysed using matrix-assisted 
laser desorption ionization-time of flight (MALDI-TOF) mass spectrometer (alpha-cyano-4-
hydroxycinnamic acid as the matrix) on a linear time-of-flight Voyager DE mass spectrometer 
(Perseptive Biosystems, MA, USA). The fractions with masses coincident with putative novel 
cDNA-encoded peptide were subjected to primary structural analysis by MS/MS 
fragmentation sequencing using an LCQ-Fleet electrospray ion-trap mass spectrometer 
(Thermo Fisher Scientific).  
R2PLx and related analogues synthesis and purification 
To investigate the effect of the ring structure, the antimicrobial peptide R2PLx was used as 
the framework to design a deletion analogue where the C-terminal hexapeptide ring was 
removed, namely R2PLx-22. In addition, for better understanding the dominant influence of 
loop domain, lysine residues at position 24 was replaced with serine to eliminate the net 
positive charge within the loop structure, namely S
-24
-R2Plx 
(GIMDTVKNAAKNLAGQLLDKLKCSITAC). Sufficient quantities to evaluate the 
bioactivities of each peptide was obtained using the automatic PS4 peptide synthesizer 
(Protein Technologies, USA) along with standard Fmoc-chemistry. Cleavage of the primary 
products from the resin and subsequent de-protection used a mixture of TFA, ethanedithiol, 
thioanisole and water (94:2:2:2 (v/v)). Prior to lyophilisation, R2PLx and S
-24
-R2Plx were 
dissolved in 0.2% of hydrogen peroxide in 0.05/19.95/80.00 (v/v/v) TFA/ water/ acetonitrile 
for 30 min to get the loop structure via sulfhydryl oxidization. Finally, each synthetic peptide 
was purified using RP-HPLC (Phenomenex C-5 column, 0.46 cm × 25 cm) and its purity was 
confirmed using MALDI-TOF mass spectrometry (Perseptive Biosystems, MA, USA).  
Circular Dichroism (CD) spectra 
The secondary structure of R2PLx and C-terminal deleted analogue were estimated using a 
CD spectrometer (Jasco J851, USA). Specifically, the parameters were 100 µM of each 
peptide, which was dissolved in 10 mM ammonium acetate (NH4AC) buffer or 50 % 
trifluoroehanol (TFE) (v/v in 10 mM NH4AC) respectively, was loaded in a cuvette (1-mm 
path length). For the analysis, three passes (“accumulation”) within the range of 190-260 nm 
were made at 20 °C at a scanning speed of 200 nm/min, a bandwidth of 1 nm, and a data pitch 
of 0.5 nm. The percentage of the α-helix structure was predicted via K2D method in 
DichroWeb website (http://dichroweb.cryst.bbk.ac.uk/html/home.shtml). 
Antimicrobial assay  
The minimal inhibitory concentration (MIC) of both synthesized peptides were determined 
against S. aureus (NCTC 10788), E. coli (NCTC 10418) and C. abicans (NCTC 1467) as well 
as the resistant microorganisms MRSA (ATCC 12493), E. faecalis (NCTC 12697) and P. 
aeruginosa (ATCC 27853), each of which had been cultured in Mueller-Hinton broth. 
Cultures of each microorganism (1×10
5
 colony forming units (CFU)/mL) were inoculated 
with peptide solutions in a concentration range of 1 to 512 μM (in two-fold dilutions) in a 96-
well plate (100 μL per well) and incubated at 37 °C in a humidified atmosphere for 16-24 h. 
Thereafter, the absorbance values of each well was determined at 550 nm using a Synergy HT 
plate reader (Biotech, USA) and the MIC was defined as the lowest concentration of the 
respective peptide that resulted in no apparent growth of the microorganism. In addition, 20 
μL of a mixture from each well was inoculated on Mueller-Hinton agar plates. The 
corresponding peptide concentration where no bacterial communities grew was defined as the 
minimum bactericidal concentration (MBC). 
MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay 
Each of the five cancer cell lines — non-small cell lung cancer H157, melanocyte MDA-MB-
435S, human prostate carcinoma PC-3, human glioblastoma astrocytoma U251MG, human 
breast cancer MCF-7 — as well as the cell line for normal human microvessel endothelial 
cells HMEC-1 were seeded into a 96-well plate at densities of 5000 cells/well. After 
incubation for 24 h at 37 ºC with 5% CO2, the cells were starved for 6 h by replacing the 
medium with serum-free medium. Thereafter, synthesised peptides (in ten-fold concentrations 
from 10
-4
 to 10
-9
 M in serum-free medium) were incubated with the cells for 24 h after which 
10 μL of MTT solution (5mg/ml) was added to each well under dark conditions. Following a 
further 4 h of incubation, 100 μL of dimethyl sulfoxide superseded medium was replaced to 
each well to dissolve the formazan crystals. The OD value of each well was read by the 
Synergy HT plate reader at 550 nm. 
The cell (PC-3 cells) loss of intracellular LDH was measured via LDH Cytotoxicity Assay Kit 
(Thermo Fisher Scientific). Equivalent cells treated with sterile water or lysis buffer (supplied 
with the kit) for 45 min served as the spontaneous and maximum LDH activity controls, 
respectively. Then, 50 μL of supernatant was collected from each well and mixed with equal 
volume of supplied reaction mixture and incubated at room temperature for 30 min. 50 μL of 
supplied stop solution was added to each well. The absorbance at 680 nm was measured using 
Synergy HT plate reader and subtracted from the 490 nm absorbance. Similarly, to obtain the 
kinetics of cytoplasmic LDH release, 50 μL of supernatant from equivalent PC-3 cells treated 
with 100 μM, 10 μM and 1 μM of R2PLx peptide, respectively, at different time points (6, 12, 
24, and 36 h), was collected and the changes in the release of cytoplasmic LDH were 
monitored. 
Annexin V-FITC/ Propidium Iodide (PI) staining assay  
The fluorescence monitoring of cellular death was evaluated through FITC Annexin V 
Apoptosis Detection Kit (BD Bioscience), based on the published method 
[12]
. Briefly, PC-3 
cells were seeded into 24-well plate (3 × 10
4
 cells/well). After 24 h incubation and 6 h serum-
starvation, the cells were treated with 5 μM of R2PLx. At different time points (0, 6 and 24 h), 
cells were supplemented with 400 μL of binding buffer containing 5 μL of Annexin V-FITC 
and 5 μL of PI , and then were incubated for 10-15 min at room temperature in the dark. 
Thereafter, analysed in images were captured by fluorescence microscopy (Leica 
Microsystems, Switzerland).  
Detection of Caspase-3 activity on PC-3 cells  
Activation of Caspase-3 in R2PLx induced prostate cancer cells was measured using EnzChek 
Caspase-3 Assay Kit (Molecular Probes, USA), according to the manufacturer’s instructions. 
Briefly, after 24 h incubation and 6 h serum-starvation as described previously, 1 × 10
6
 cells 
of PC-3 cells was treated with 5 μM of R2PLx for 6 h. Equivalent cells treated with serum-
free medium served as control group. Each cell sample was resuspended in 50 μL of the 1X 
cell lysis buffer (supplied with the kit) and set on ice for 30 min. Thereafter, 50 μL of each 
supernatant (centrifuged at 2,500 ×g for 5 min at 4 ºC) was mixed thoroughly with an equal 
volume of 2X reaction buffer (supplied with the kit) and incubated for 1.5h. In addition, 50 
μL of the 1X cell lysis buffer was taken as the background fluorescence of the substrate. The 
fluorescence intensity was measured (excitation at 360 nm and emission at 460 nm) using an 
ELISA plate reader (Biolise BioTek EL808).   
 
Haemolysis assay 
To determine the toxicity of the peptides to normal mammalian cells, a 2% solution of horse 
erythrocytes was re-suspended in phosphate-buffered saline (PBS) solution and incubated 
with each peptide at the standard concentrations (i.e., from 1 to 512 μM) for 2 h at 37 ºC. 
Equivalent cells treated with PBS or 1% Triton X-100 served as the positive and negative 
controls, respectively. Following centrifugation at 900 × g for 5 min, 100 μL of the 
supernatant from each tube was transferred to a 96-well plate, which was then read at 550 nm 
using the Synergy HT plate reader.  
Statistical analyses 
Statistical analyses of all bioactivity assays were performed using Prism 6 (GraphPad 
Software, USA). Data points represent the average of three independent experiments with 
error bars presenting the standard error of the mean (SEM).  
RESULTS 
Molecular cloning of biosynthetic precursor encoding cDNA and structural 
characterisation of R2PLx peptide from RP-HPLC fraction of skin secretion 
The nucleotide sequence of a full-length biosynthetic precursor-encoding cDNA was 
consistently cloned among the secretion-derived cDNA library (Figure 1), compromising 71 
amino acid residues. From the translated open-reading frame, the typical signal peptide 
consisting of 22 amino acid residues, was determined through NCBI-BLAST. The typical 
convertase processing site, -KR-, indicates the start of the mature peptide. The mature 28-mer 
peptide, which we have named R2PLx, also appears to have a C-terminus which is subjected 
to post-translational modification with a disulphide cysteine-loop (present in and accounted 
for by molecular mass in MS afterwards). The R2PLx biosynthetic precursor encoding cDNA 
has been deposited in the NCBI Database (accession code; MG872823) and the presence of 
the mature R2PLx peptide in the secretions was further confirmed by RP-HPLC isolation and 
MS/MS fragmentation sequencing, with the retention times at 128 min (Figure 2).  
 
 
 
 
FIGURE 1. Nucleotide sequence and corresponding translated ORF of precursor cDNA 
cloned from the pickerel frog (Rana palustris) tegmental secretion library which encodes 
R2PLx peptide. The putative signal peptide and mature peptide are labelled by single-
underline and double-underline respectively. The asterisk corresponds to the stop codon. The 
cDNA sequence has been deposited in the NCBI Database (accession code; MG872823). 
 
 
 
  M  F  T  T   K  K  S   M  L  L   F  F  F  L   G  T  I  
    1 ATGTTCACCA CAAAGAAATC CATGTTACTC TTTTTCTTTC TTGGGACCAT 
 TACAAGTGGT GTTTCTTTAG GTACAATGAG AAAAAGAAAG AACCCTGGTA 
   S  L  S   L  C  E  Q   E  R  G   A  D  E   D  D  G   
   51 CTCCTTATCT CTCTGTGAAC AAGAGAGAGG TGCAGATGAA GACGATGGTG 
 GAGGAATAGA GAGACACTTG TTCTCTCTCC ACGTCTACTT CTGCTACCAC 
 V  E  M  T   E  E  E   V  K  R  G   I  M  D   T  V  K 
  101 TGGAAATGAC AGAGGAAGAA GTAAAAAGAG GTATCATGGA TACGGTTAAG 
 ACCTTTACTG TCTCCTTCTT CATTTTTCTC CATAGTACCT ATGCCAATTC 
  N  A  A  K   N  L  A   G  Q  L   L  D  K  L   K  C  K  
  151 AATGCAGCAA AGAATTTGGC CGGACAGTTG CTGGATAAGT TAAAATGTAA 
 TTACGTCGTT TCTTAAACCG GCCTGTCAAC GACCTATTCA ATTTTACATT 
   I  T  A   C  * 
  201 AATTACTGCA TGTTAAAACT TGAGTTATAT TGTTTAGCTA AATGCTAAAT 
 TTAATGACGT ACAATTTTGA ACTCAATATA ACAAATCGAT TTACGATTTA 
  251 GTTTAATAAA AATAACATCA CAAAAAAAAA AAAAAAAAAA 
 CAAATTATTT TTATTGTAGT GTTTTTTTTT TTTTTTTTTT 
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
1 58.03 29.52 G 28
2 171.11 86.06 I 2903.59 1452.30 27
3 302.15 151.58 M 2790.50 1395.76 26
4 417.18 209.09 D 2659.46 1330.24 25
5 518.23 259.62 T 2544.44 1272.72 24
6 617.30 309.15 V 2443.39 1222.20 23
7 745.39 373.20 K 2344.32 1172.66 22
8 859.43 430.22 N 2216.23 1108.62 21
9 930.47 465.74 A 2102.18 1051.59 20
10 1001.51 501.26 A 2031.15 1016.08 19
11 1129.60 565.31 K 1960.11 980.56 18
12 1243.65 622.33 N 1832.01 916.51 17
13 1356.73 678.87 L 1717.97 859.49 16
14 1427.77 714.39 A 1604.89 802.95 15
15 1484.79 742.90 G 1533.85 767.43 14
16 1612.85 806.93 Q 1476.83 738.92 13
17 1725.93 863.47 L 1348.77 674.89 12
18 1839.02 920.01 L 1235.69 618.35 11
19 1954.04 977.53 D 1122.60 561.80 10
20 2082.14 1041.57 K 1007.57 504.29 9
21 2195.22 1098.11 L 879.48 440.24 8
22 2323.32 1162.16 K 766.40 383.70 7
23 2426.33 1213.67 C 638.30 319.65 6
24 2554.42 1277.71 K 535.29 268.15 5
25 2667.50 1334.26 I 407.20 204.10 4
26 2768.55 1384.78 T 294.11 147.56 3
27 2839.59 1420.30 A 193.06 97.04 2
28 C 122.03 61.52 1
R2PLx
FIGURE 2. Full region of RP-HPLC chromatogram of pickerel frog (Rana palustris) skin 
secretion. The retention time of R2PLx is shown by the arrow. The masses of corresponding b 
and y ions derived from R2PLx in the table are indicated in red and blue, respectively.  
 
Synthesis and secondary structure analysis  
Although ranatuerins possess the “rana box” domain at their C-terminii which is also present 
in other peptide families from the brevinin superfamily, the structural characteristics, 
especially the amino acid constitution of the “rana box”, are variable. Therefore, to further 
investigate the influence of the “rana box” of R2PLx on its biological activity, both R2PLx 
and the “rana box” deleted analogue, R2PLx-22, were synthesised and purified (Table 1). The 
CD spectra of both peptides shows the pattern of random coil in aqueous solution and a 
typical α-helix CD spectra in 50% of TFE solution (Figure 3). Obviously, R2PLx shows a 
more negative peak at 222 nm and 208 nm than R2PLx-22, indicating larger α-helical content 
formed in the membrane-mimetic environment. The calculation of helicity of R2PLx is nearly 
two-fold then which of R2PLx-22 (Table 1).   
 TABLE 1. The amino acid sequences and the calculated α-helicity in 50% of TFE solution of 
R2PLx and the analogue. 
Peptide Sequence α-helix in 50% TFE (%)           
R2PLx GIMDTVKNAAKNLAGQLLDKLKCKITAC 78 
R2PLx-22 GIMDTVKNAAKNLAGQLLDKLK 40 
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FIGURE 3. CD spectra of R2PLx (Blue) and R2PLx-22 (Red) in different solutions. The CD 
spectra in 50% TFE/10mM NH4AC solution and 10mM NH4AC buffer at 20 ºC are indicated 
by dotted and solid line, respectively.  
Antimicrobial activity  
R2PLx and its two analogues have antimicrobial activity against five of the six 
microorganisms tested (Table 2). R2PLx shows higher potency than the truncated analogue 
on all the tested microorganisms except P. aeruginosa. R2PLx also exhibits antimicrobial 
activity towards MRSA, although, this activity is less potent than that toward the wild-type S. 
aureus. These results would indicate the removal of the ‘rana box’ markedly decreases the 
antimicrobial activity of the parent peptide. Surprisingly, the deficiency of cationic amino 
acid inside such motif, greatest impairs the antibacterial activity of this rana-box AMP. 
TABLE 2. Antimicrobial 
activity of R2PLx peptide and 
MIC/MBC (µM) 
R2PLx R2PLx-22 S
-24
-R2PLx 
its analogues against various 
microorganismsMicroorganis
ms 
S. aureus (NCTC 10788) 32/128 256/256 >512/>512  
E. coli (NCTC 10418) 32/64 128/256 512/>512  
C. albicans (NCTC 1467)  256/512 512/>512  >512/>512  
MRSA (ATCC 12493) 256/512 >512/>512  >512/>512  
E. fecalis (NCTC 12697) 128/512 >512/>512  >512/>512  
P. aeruginosa (ATCC 27853) >512/>512  >512/>512  >512/>512  
 
Antiproliferative activity 
R2PLx exhibits a dose-dependent inhibitory effect on the proliferation of the five tested 
human cancer cell lines (Figure 4). It inhibited the proliferation of these cell lines with IC50s 
ranging from 5.79 to 20.19 µM (Table 3). R2PLx-22 and S
-24
-R2PLx did show some activity 
against these cancer cells, but both were much less potent than R2PLx, indicating the 
alteration in loop domain of the C-terminus dramatically reduces its anti-proliferative activity. 
The impact of R2PLx on the normal cell line HMEC-1 was also examined, and whilst it did 
have an impact upon the proliferation of these cells, it was much less potent toward these cells 
(IC50 79.50 µM) than it was towards the cancer cells.   
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FIGURE 4. The cell viability of selected cell lines when treated with various concentrations 
of R2PLx (red), R2PLx-22 (blue) and S
-24
-R2PLx (green). (A) H157, non-small cell lung 
cancer, (B) MBD-MB-435, melanocyte, (C) PC-3, human prostate carcinoma cell line, (D) 
U251MG, human glioblastoma astrocytoma, (E) MCF-7, human breast cancer cell line, and 
(F) HMEC-1, normal human microvessel endothelial cells. The curves were fitted using 
normalised dose-response algorithm. The error bar represents the SEM of 9 replicates, and the 
statistical significance was verified using one-way ANOVA, and it is illustrated in Table S1. 
 
TABLE 4. The calculated IC50s of R2PLx and its two analogues were calculated from the 
normalized curves in Figure 4. 
Human Cell lines IC50(μM) 
R2PLx R2PLx-22 S
-24
-R2PLx 
H157 5.90 843.40 58.18 
  MBD-MB-435s 15.44 872.70 179.00 
PC-3 5.79 283.90 792.60 
U251-MG 16.14 104.10 278.30 
MCF-7 20.19 109.30 316.90 
HMEC-1 79.50 588.20 1185.00 
 
 
Haemolysis activity  
R2PLx was found to possess moderate haemolytic activity in regard to horse erythrocytes, 
with less than 50% haemolysis at the highest concentration used in this assay. Indeed, the 
haemolytic activity of R2PLx was less than 5% at the IC50s against H157 and PC-3 cells, and 
less than 15% at the MICs for E. coli and S. aureus. Both analogues resulted in less 
haemolysis, even at higher concentrations, while the substituted analogue demonstrate 
minimal toxicity toward healthy mammalian cells (Figure 4 and 5).  
 
FIGURE 5. Haemolytic activity of R2PLx (red), R2PLx-22 (blue) and S
-24
-R2PLx (green) 
against the horse erythrocytes, presented by solid and striping columns, respectively. The 
percentage is obtained by the comparison of haemolysis induced by 1% Triton X-100. The 
error bar represents the SEM of 3 replicates. 
 
R2PLx-induced apoptosis on PC-3 cancer cell 
In order to further study the antiproliferative activity of R2PLx, PC-3 cells were used as 
R2PLx showed its most potent effect on these cells. The rate of LDH release causing by 
R2PLx in PC-3 cells is less than 40% of maximum LDH released control (lysis buffer) at the 
highest concentration, which induces almost 100% of inhibition on cell viability (Figure 6A). 
Meanwhile, the kinetics of cytoplasmic LDH release from cancer cells were observed, 
whereas, at low peptide concentration ranging 10 µM to 1 µM, there are no significant LDH 
leakage within 12 h (Figure 6C). In other words, the anti-proliferation of cancer cell 
mechanism of action by R2PLx was not largely correlated with the disruption of plasma 
membrane integrity. To further investigate the mechanism of action of R2PLx, Annexin V-
FITC/PI staining was used to evaluate morphological changes in treated cells (Figure 6B). 
After 6 h challenge, phosphatidylserine (PS) exposure on membrane was visible in green via 
binding with Annexin V-FITC. Following 24 h incubation, most cells stained by both. 
Annexin V- FITC and PI positive indicated that R2PLx was exerting its anti-proliferative 
effects through a mechanism involving apoptotic processes. Furthermore, the Caspase-3 
activity was also observed after 6 h treatment with R2PLx (Figure 6D) and was found similar 
to Annexin V-FITC/PI staining results, as well as the low LDH leakage at 6h (Figure 6C), 
suggesting R2PLx-induced cancer cell death involved in the activation of intrinsic apoptotic 
pathway.  
  
FIGURE 6. (A) The effect of R2PLx on PC-3 cells was estimated on both LDH (blue) and 
MTT (red) assays. The percentage of LDH cytotoxicity and MTT viability were obtained by 
compared to positive group (treated with lysis buffer) and growth control group ( treated with 
medium). The error bar represents the SEM of 3 replicates. (B) Annexin V-FITC/PI staining 
of PC-3 cells were evaluated after treating with R2PLx peptide at the IC50 value over different 
time scales. (C) Cytoplasmic LDH release of PC-3 cells treated with 100 µM (red), 10 µM 
(blue) and 1 µM (green) of R2PLx at 6h, 12h, 24h and 36h respectively. (D) Caspase-3 
activity on PC-3 cells after 6 h incubation with 5 µM R2PLx (black) with respect to untreated 
cells (gray). 
DISCUSSION 
In this study, the R2PLx peptide was cloned from pickerel frog skin secretions and the 
presence of the mature peptide was confirmed by LC-MS/MS. In the various biological assays 
performed, R2PLx demonstrated broad-spectrum antimicrobial activity, along with moderate 
haemolytic effects, results which are similar to the other ranatuerin-2 peptides, such as 
ranatuerin-2TRa, ranatuerin-2Ma or -2Mb 
[13, 14]
. So far, it is unclear how these AMPs impact 
upon microorganisms and cancer cells, but AMPs generally exhibit a non-specific interaction 
with bacterial cell membranes, or mammalian plasma membranes, leading to the loss of 
integrity and ultimately disintegration of the cell 
[15]
. Although this study did not explore the 
antibacterial mechanism of R2PLx, extensive investigations have indicated that cationic 
AMPs possess selective toxicity toward a variety of bacteria and fungi due to the 
characteristics of the microbial cell membranes, such as the negative charge 
[15, 16]
, which 
allows the cationic AMPs to aggregate on the bacterial cell surface by electrostatic attraction. 
By contrast, mammalian cell membranes are largely composed of cholesterol and zwitterionic 
phospholipids, thereby reducing their attractiveness to cationic AMPs 
[17]
.  
    AMPs have also shown great potential as new anticancer therapeutics 
[18, 19]
, and here 
indeed, R2PLx can potently inhibit the proliferation of tumour cells. It is generally proposed 
that the antiproliferative mechanism of AMPs on cancer cells is similar to their antimicrobial 
action, based upon the observation that tumour cells can also possess a negatively charged 
membrane 
[20]
. Indeed, here the activity of R2PLx against cancer cells is more potent than its 
antimicrobial activity. In addition, the observation that its IC50 against the cancer cells is at 
least four fold lower than against the HMEC-1 normal cells, and there is limited haemolysis at 
these values, indicates these peptides are selective towards the cancer cells. Also, the lack of 
haemolysis at the IC50 values for the cancer cells could indicate the mechanism of action of 
these peptides may not be related to membrane-lytic activity 
[21]
. Almaaytah and coworkers 
also performed same dual staining method and indicated that AamAP-S1 peptide was not 
killing cells through apoptosis induction as they observed both AnnexinV-FITC and PI 
positive results 
[22]
; however, they only displayed the results after 24 h drug treatment. It is 
believed that, in the earlier events of apoptosis, translocation of membrane PS from the inner 
side (but integrated plasma membrane) can merely cause AnnexinV-FITC positive and 
subsequently the loss of membrane integrity occur in the late period, which leading both 
AnnexinV-FITC and PI positive 
[23-25]
. In other words, although translocation of PS at the 
external cell surface is present in apoptosis and necrosis, the cell membrane remains intact 
during the initial stages of apoptosis. Herein, our observation (AnnexinV-FITC positive /PI 
negative in 6 h and both AnnexinV-FITC /PI positive in 24 h) was consistent with above 
dynamic process. Hence, we indicated that the selective cytotoxicity of R2PLx towards the 
cancer cells is associated with non-membranolytic action. Moreover, we also observed the 
significant Caspase-3 activity in R2PLx-induced PC-3 cancer cells after 6 h treatment, which 
is supposed to be the early apoptosis stage, implying R2PLx is able to trigger apoptosis cell 
death. In fact, previous research indicated that the change of membrane surface charge in 
malignant cells (the inner leaflet membrane of normal cell is relatively anionic and negative 
than outer) plays a key role in signalling protein (i.g., K-ras) localization and activity, 
inspiring cancer cell ability to grow 
[17, 26]
. It is evident that, apart from larger negative charge 
on the malignant cell surface due to higher content of anionic molecules, such as O-
glycosylated mucins, sialylated gangliosides and heparan sulphate, greater number of 
microvillus increasing surface area helps the accumulation of cationic peptides on the cancer 
cell membrane 
[27]
. From these terms, it is possible for cationic R2PLx peptide to act on acid 
phospholipid and form lipid-peptide domain: finally such change may localize signalling 
protein to plasma membrane, further regaining apoptosis signalling for cancer cells and 
leading cell death. Also, one of the possibility is that R2PLx might be able to bind the cell-
surface death receptors (such as CD95, DR4 and DR5) as pro-apoptotic ligand, thereby 
inciting a cascade of intracellular signalling 
[28]
. Alternatively, it is possible that R2PLx 
translocates into the cell and could be capable of interfering with intracellular organelles 
and/or molecules 
[17]
. Indeed, a previous report from Cruz-Chamorro and colleagues found 
that magainin-1 induced apoptosis in leukaemia cells by entering the cell and causing release 
of cytochrome c from mitochondria 
[29]
. 
   We also observed that removal of the ‘rana box’ from this peptide decreased its 
bioactivities considerably. Among the naturally-occurring AMPs from Ranidae, the “rana 
box” structure is prevalent among the major families which include ranatuerin-1, brevinin-1 
and -2, esculentin-1 and -2, ranalexin, vigrocin and paluserin 
[30]
. However, the amino acid 
sequence of these rana box domains have been shown to consist of 6 to 11 residues in diverse 
constitutions 
[31]
. Moreover, the importance of the rana box to the bioactivities of these 
peptides are variable, with the removal of this domain decreasing the antimicrobial activity of 
brevinin 
[32]
, but not impacting upon the function of Esculentin-1 
[33]
. Therefore, the study of 
the “rana box”-deleted analogue, R2PLx-22, was necessary to illustrate the influence of the 
rana box on the bioactivity of ranatuerin peptides. Our investigations indicated that the loss of 
net positive charge of R2PLx (both R2PLx-22 and S
-24
-R2PLx) demonstrates more less 
toxicity towards normal mammalian cells, along with less potent antibacterial and 
antiproliferative activities. On the other hand, the reservation of loop structure, but the 
absence of cationic amino acid within this domain maximum reduces the antibacterial effect, 
in comparison of other analogue, indicating that cationicity of rana-box domain is also crucial 
for maintaining its biological activities. Indeed, the heptapeptide C-terminal
 “rana box” was 
found to be important for maintaining both the antimicrobial and antiproliferative activity of 
this peptide. However, there is no agreed understanding regarding the exact role of such an 
intramolecular disulphide-bridge cysteine motif. Subasinghage et al. 
[34]
 used solid-state 
nuclear magnetic resonance spectroscopy to analyse its structure in ranatuerin-2CSa, and they 
found the rana-box domain possesses a helix structure. Our CD spectra also proved that the 
removal of the rana-box markedly reduced the amount of helical conformation within this 
peptide. Accordingly, the rana-box loop of ranaturein-2 might participate in the formation of 
an α-helical structure in lipid membranes that correlates with antimicrobial activity and 
antiproliferative potency, although, this will require confirmation. 
    In summary, these results indicate R2PLx is a potential candidate as an effective agent to 
target cancer cells given its apoptotic action and selective toxicity to human cancer cells. In 
addition, we have also shown that, as observed in a previous study 
[35]
, the rana box in the C-
terminus of R2PLx, as well as the net positive charge, are essential for maintaining the 
biological potency of this peptide family. 
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Supporting Information 
Table S1. Two-way ANOVA analysis of the effect on cell proliferation of R2PLx and the 
analogues on the cancer cell lines H157, PC-3, U251MG, and MCF-7 as well as HMEC-1. * 
p<0.05; ** p<0.01; *** p<0.001 and **** p<0.0001; ns: no significance. 
 
Tukey's multiple 
comparisons test 
H157 MBD-
MB-435S 
PC-3 U251-MG MCF-7 HMEC-1 
Log peptide (M) = -4.       
R2PLX vs. R2PLX-22 **** **** **** **** *** **** 
R2PLX vs. S-24-R2PLX * **** **** **** **** **** 
R2PLX-22 vs. S-24-R2PLX *** * ns *** * ns 
Log peptide (M) = -5.       
R2PLX vs. R2PLX-22 **** ** **** * ns ns 
R2PLX vs. S-24-R2PLX *** * **** **** * ns 
R2PLX-22 vs. S-24-R2PLX ns ns ns *** ns ns 
Log peptide (M) = -6.       
R2PLX vs. R2PLX-22 ns ns ns ns ns ns 
R2PLX vs. S-24-R2PLX ns * ns ns ns ns 
R2PLX-22 vs. S-24-R2PLX ns ns ns ns ns ns 
Log peptide (M) = -7.       
R2PLX vs. R2PLX-22 ns ns ns ns ns ns 
R2PLX vs. S-24-R2PLX ns ns ns * ** ns 
R2PLX-22 vs. S-24-R2PLX ns ns ns ns ns ** 
Log peptide (M) = -8.       
R2PLX vs. R2PLX-22 ns ns ns ns ns ns 
R2PLX vs. S-24-R2PLX * ns ns * ns ns 
R2PLX-22 vs. S-24-R2PLX ns ns ns ns ns ns 
Log peptide (M) = -9.       
R2PLX vs. R2PLX-22 ns ns ns ns ns ns 
R2PLX vs. S-24-R2PLX *** ns ns ns ns ns 
R2PLX-22 vs. S-24-R2PLX ns ns ns ns ns ns 
 
 
